Clinical trial · Observational
Studying Tumor Tissue Samples and Blood Samples to Learn More About DNA Changes in Patients With Lung Cancer
EGFR Pathway Mutations in Lung Cancer Patient Tumors and Blood
NCT00899405CI-TRIAL-00115852recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This laboratory study is looking at tumor tissue samples and blood samples to learn more about DNA changes in patients with lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Patients with lung cancer
- description
- Collection of archival tumor specimen at the beginning of the study and collection of blood samples at the beginning of the study and then at regular intervals
Primary outcomes (1)
- measure
- Mutational status of the EGFR pathway
- timeFrame
- up to 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed lung cancer PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * May have received prior EGFR inhibitors
References
Publications (0)
Data not yet available
No reference posted for this study.